The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults.
about
Adhesion and Invasion of Gastric Mucosa Epithelial Cells by Helicobacter pyloriTreatment of Helicobacter pylori infection 2016.Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance.Consensus on the clinical management, screening-to-treat, and surveillance of Helicobacter pylori infection to improve gastric cancer control on a nationwide scale.Utility of normalized genome quantification of Helicobacter pylori in gastric mucosa using an in-house real-time polymerase chain reactionFirst-line therapies for Helicobacter pylori eradication: a critical reappraisal of updated guidelinesEfficacy and safety of high dose dual therapy for Helicobacter pylori rescue therapy: A systematic review and meta-analysis.A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori.Antibiotic susceptibility, heteroresistance, and updated treatment strategies in Helicobacter pylori infection.Decline in prevalence and risk of helicobacter pylori in kidney transplant recipients: A systematic review and meta-analysis.Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis.Identification of Helicobacter pylori and the evolution of an efficacious childhood vaccine to protect against gastritis and peptic ulcer disease.Helicobacter pylori-Induced Changes in Gastric Acid Secretion and Upper Gastrointestinal Disease.Probiotics as an adjuvant treatment in Helicobacter pylori eradication therapy.Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies.Role of LPS-elicited signaling in triggering gastric mucosal inflammatory responses to H. pylori: modulatory effect of ghrelin.Practical considerations for managing Helicobacter pylori in college health.ACG and CAG Clinical Guideline: Management of Dyspepsia.Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature.Treatment of Helicobacter pylori infection 2017.Transparency ethics in practice: Revisiting financial conflicts of interest disclosure forms in clinical practice guidelines.Efficacy of three-in-one capsule bismuth quadruple therapy for Helicobacter pylori eradication in clinical practice in a multinational patient population.Limited effectiveness with a 10-day bismuth-containing quadruple therapy (Pylera® ) in third-line recue treatment for Helicobacter pylori infection. A real-life multicenter study.The diagnosis and management of H. pylori infection in Singapore.A Novel Stool PCR Test for Helicobacter pylori May Predict Clarithromycin Resistance and Eradication of Infection at a High Rate.New bismuth-containing quadruple therapy in patients infected with Helicobacter pylori: A first Italian experience in clinical practice.ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.Role of concomitant therapy for Helicobacter pylori eradication: A technical note.In H. pylori- infected patients second-line treatment with sequential levofloxacin therapy was more effective than levofloxacin triple therapy but was still suboptimal.Noninvasive molecular analysis of Helicobacter pylori: Is it time for tailored first-line therapy?Efficacy and safety of sequential versus quadruple therapy as second-line treatment for helicobacter pylori infection-A randomized controlled trialHelicobacter pylori best treatment approach: should a national consensus be the best consensus?Comparative analysis of the Hom family of outer membrane proteins in isolates from two geographically distinct regions: The United States and South Korea.Evaluation of first-line bismuth-containing 7-day concomitant quintuple therapy for Helicobacter pylori eradication.Probiotic monotherapy and Helicobacter pylori eradication: A systematic review with pooled-data analysis.Rescue therapy with bismuth quadruple regimen in patients with Helicobacter pylori -resistant strains.Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?Are optic nerve heads of patients with helicobacter pylori infection more susceptible to glaucomatous damage?Treatment of Helicobacter pylori infection: A clinical practice update.Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori.
P2860
Q28080151-DCCF1B60-BF98-44AA-A524-74B6CDCC1C91Q30248450-9D8CC7C0-0A00-46FF-B4D1-77EE4D6D8B0EQ33639114-09A546C4-1168-488A-A938-69F95AC3B695Q33698340-A60AE763-FB8D-4AB7-B0F4-601173973255Q33757695-3EB91F9E-A3BB-4121-8B3D-76BBA7D297F1Q33822948-C01E10A9-7FAC-4007-9E00-34494C17062EQ36224538-10533166-6ACE-485F-A0F0-E6E28E1AB8CDQ37697753-642A35EB-D512-4AF6-A3FB-572FD56D5FFCQ38621376-37763A02-5FB6-479F-B875-E80D79B9097BQ38808526-B52983DE-A798-47A2-BCFE-3F440BC27863Q38865607-A0F1CFF6-C1D6-4C1B-B66C-8445F2328EE8Q38971911-C6BA6522-B3D0-4F9E-B3A8-1CB77D2A8A59Q39104046-F86798D1-DE7B-419F-9C83-FE453E9D2F59Q39179173-C09E4D8D-44C6-4303-967C-8C092CCCBDA4Q39278632-036F8C31-BD0E-41A8-A6CD-6737E9222A59Q39314241-33FBF811-141C-4208-B2DC-0386A970983EQ39378424-A3FC993C-A846-4C88-A504-0C07F2F1AFE7Q39385451-7F401E21-5FE9-47B9-A3A2-82D901E9E145Q39406352-555AF324-2067-4A84-B0B9-AAC0663B9D81Q40054316-8E64158C-60E2-4C7C-A737-7744D00F9CC1Q40070335-5A3E9E4F-7665-418B-8B44-CFB0CDF5FA5FQ40082686-F9443203-6975-498E-B5FD-69CB5D918966Q40108161-EDD635F3-5F81-41F4-8771-5BE54167A6D4Q40201360-E666BB67-5249-438D-808A-A7E276AE73C6Q40208727-D9AE847B-1043-4CC0-8788-691E1C3162E9Q40357081-3E8635C6-1FDF-4268-B656-5823C8DE6D77Q40378087-A5671263-A25A-4EEE-80D5-5C64D55DE3DDQ40482860-ADECE8E8-E1C9-4745-B338-2646BB546CCAQ40621812-C2CD14F1-4266-4B48-A315-6924E27CE6F3Q42362197-5C9DA26F-596C-44AB-9858-BDADFDED1610Q42366183-88F1CDC1-23D6-43B7-AB76-94D1A06BB588Q45743239-73A5E921-EEF2-4D21-AF28-906FDA4F62F2Q47189220-5CF234CA-E127-4D80-A93D-C5E6264482C9Q47222389-81CD56B6-A5BB-45F2-BDEA-78BCF09A2151Q47650511-B0671CC9-F571-4DD5-9F8F-022CCB7B2541Q47671478-5700CFD8-ACDB-448C-9ADE-B3B13E6F45FBQ48104849-650CC4D7-4E9B-4701-B1FA-D69A85685866Q48239888-7E4712EC-01BF-4B42-9A11-B5FA8B46A691Q48291323-B8C84C82-184C-4D49-B995-8810709C6C04Q48291731-C596C650-2208-4930-846E-20B70BEBD8FE
P2860
The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults.
description
2016 nî lūn-bûn
@nan
2016 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults.
@ast
The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults.
@en
type
label
The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults.
@ast
The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults.
@en
prefLabel
The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults.
@ast
The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults.
@en
P2093
P1433
P1476
The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults.
@en
P2093
Carlo A Fallone
Craig Render
Grigorios I Leontiadis
Javier P Gisbert
John K Marshall
Lori Fischbach
Naoki Chiba
Nicola L Jones
Richard H Hunt
P304
P356
10.1053/J.GASTRO.2016.04.006
P407
P577
2016-04-18T00:00:00Z